PROTHENA CORPORATION PLC – Trademark Portfolio
Entity Type: 99
PROTHENA CORPORATION PLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 45 (Legal & Security Services) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PROTHENA. The owner is based in Dublin 2.
77 Sir John Rogerson's Quay
Block C, Grand Canal Docklands
Dublin 2 D02 VK60 , IE
Showing of trademarks Trademarks
Trademark Classifications
PROTHENA CORPORATION PLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PROTHENA CORPORATION PLC have?
PROTHENA CORPORATION PLC has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does PROTHENA CORPORATION PLC file in?
PROTHENA CORPORATION PLC files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are PROTHENA CORPORATION PLC's most well-known trademarks?
PROTHENA CORPORATION PLC's registered trademark portfolio includes well-known marks such as PROTHENA. These are among 3 currently registered trademarks in the portfolio.
What is PROTHENA CORPORATION PLC's trademark registration success rate?
PROTHENA CORPORATION PLC has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.